IN8bio reports 100% AML CR rate with INB-100 at ASH; no relapses after median 19.7 months

IN8BIO, INC.

100% of AML patients (n=10) remain in complete remission after median 19.7 months follow-up; no relapses or new deaths as of Sept 30, 2024.
INB-100 shows durable in vivo expansion and persistence of allogeneic gamma-delta T cells at 365 days post single dose.
No CRS, neurotoxicity (ICANS), or dose-limiting toxicities observed; low-grade GvHD steroid-responsive in 60% of patients.
Expansion cohort enrollment ongoing at DL2 (RP2D); updated data expected first half 2025.
Three patients in CR >3 years, one progression-free >4 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.